Management of Myositis-Related Interstitial Lung Disease.
Interstitial lung disease (ILD) is a frequent pulmonary manifestation and an important cause of morbidity and mortality in patients with idiopathic inflammatory myopathy. Myositis-related ILD presents a therapeutic challenge for clinicians, as there are no available guidelines to help with management decisions. This review covers the existing evidence on the pharmacologic and nonpharmacologic management of myositis-related ILD, highlighting the lack of randomized controlled data to guide treatment. Given the absence of existing guidelines to inform treatment decisions, we provide a comprehensive summary, including dosing, side effects, and suggested monitoring of the commonly used immunosuppressive agents and a proposed treatment algorithm based on the existing literature.
Department of Medicine, University of California San Francisco, San Francisco, CA.
Julie
J
Morisset
Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, MD.
Cheilonda
C
Johnson
Département de Médecine, Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada.
Eric
E
Rich
Department of Medicine, University of California San Francisco, San Francisco, CA.
Harold R
HR
Collard
Department of Medicine, University of Colorado Denver, Aurora, CO. Electronic address: joyce.lee@ucdenver.edu.
Joyce S
JS
Lee
D000465:Algorithms; D015415:Biomarkers / Q000032:analysis; D003952:Diagnostic Imaging; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D017563:Lung Diseases, Interstitial / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy*; D009220:Myositis / Q000150:complications* / Q000175:diagnosis
D015415:Biomarkers; D007166:Immunosuppressive Agents
interstitial lung disease; myositis; treatment